HHS Reviewing Vaccine Recommendation Framework and Shared Clinical Decision-Making

HHS has opened a Request for Information on how the federal government categorizes vaccine recommendations — pulling apart the framework that currently distinguishes routine, risk-based, and shared clinical decision-making into something explicitly up for debate. For anyone running pediatric immunology clinics, the SCDM lane is where the regulatory edges have always frayed. That is precisely where this RFI will land.

What the request actually covers

Childhood vaccination is named explicitly. The three lanes under review form the backbone of how ACIP guidance reaches clinicians and families. Routine means the default immunization schedule applies without further condition. Risk-based identifies targeted populations defined by exposure, occupation, or medical condition. Shared clinical decision-making places the conversation between clinician and patient — or in pediatrics, between clinician and parent — and expects the recommendation to emerge from that exchange rather than from a population-level default.

Where pediatric immunology patients get caught

In my experience running these cohorts, SCDM is the designation that immunocompromised children fall through most often. Their guardians are rarely handed a default schedule; they are handed a discussion. When that conversation rests on solid specialty guidance, it works. When payer reimbursement and drug access are pinned to an ambiguous category, children with primary immunodeficiencies absorb the friction — in delayed vaccines, prior authorization denials, or clinicians declining to initiate certain immunizations because the documentation burden exceeds the available evidence base for atypical immune profiles.

If HHS is treating SCDM as subject to genuine redefinition, this RFI is the rare moment to pressure a category that has long lacked operational clarity. Pediatric immunologists, family practitioners treating PID patients, and patient advocacy organizations have more leverage in a federal comment period than they typically get from formal regulatory channels. The window matters more than the venue.

What to actually put in the comments

Useful submissions will not register preferences. They will do something harder: document adverse events observed in real-world pediatric populations, name where risk-based criteria fail atypical presentations, flag how category language translates into insurer behavior, and call out the cohort-level evidence gaps that keep SCDM recommendations from being actionable in primary care. HHS is not running a popularity vote. They are asking for substantiated input that survives clinical and methodological scrutiny — and the most credible voices in that room are the clinicians already managing these decisions at every visit, not the commentators forming opinions about them from the outside.